Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.
4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback